These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8080984)

  • 1. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
    Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T
    Blood; 1994 Sep; 84(6):1765-74. PubMed ID: 8080984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.
    Kuzel TM; Rosen ST; Gordon LI; Winter J; Samuelson E; Kaul K; Roenigk HH; Nylen P; Woodworth T
    Leuk Lymphoma; 1993 Nov; 11(5-6):369-77. PubMed ID: 8124209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
    Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
    Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
    Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
    Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
    Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
    J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.
    Prince HM; Martin AG; Olsen EA; Fivenson DP; Duvic M
    Leuk Lymphoma; 2013 Jan; 54(1):69-75. PubMed ID: 22738414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
    LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
    Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes.
    Salard D; Kuzel TM; Samuelson E; Rosen S; Bakouche O
    J Clin Immunol; 1998 May; 18(3):223-34. PubMed ID: 9624582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma.
    Hesketh P; Caguioa P; Koh H; Dewey H; Facada A; McCaffrey R; Parker K; Nylen P; Woodworth T
    J Clin Oncol; 1993 Sep; 11(9):1682-90. PubMed ID: 8355035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.
    Moreland LW; Sewell KL; Trentham DE; Bucy RP; Sullivan WF; Schrohenloher RE; Shmerling RH; Parker KC; Swartz WG; Woodworth TG
    Arthritis Rheum; 1995 Sep; 38(9):1177-86. PubMed ID: 7575710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.
    LeMaistre CF; Craig FE; Meneghetti C; McMullin B; Parker K; Reuben J; Boldt DH; Rosenblum M; Woodworth T
    Cancer Res; 1993 Sep; 53(17):3930-4. PubMed ID: 8358720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
    Kazin R; Bujanauskas P; Vonderheid EC
    J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
    [No Abstract]   [Full Text] [Related]  

  • 16. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
    Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
    Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
    Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
    Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
    LeMaistre CF; Saleh MN; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Nichols JC
    Blood; 1998 Jan; 91(2):399-405. PubMed ID: 9427692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.